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Abstract: Endothelial dysfunction is the common link between cardiovascular disease risk 
factors and the earliest event in the cascade of incidents that results in target organ damage. 
Angiotensin II, the terminal pressor effector arm of the renin-angiotensin-aldosterone system, 
increases blood pressure (BP) by vasoconstriction and sodium and ﬂ  uid retention, and has a 
pro-oxidative action that induces endothelial dysfunction and contributes to vascular remodeling. 
Angiotensin receptor blockers (ARBs) reduce BP and morbidity and mortality in patients 
with hypertension, ventricular hypertrophy, diabetes mellitus, and renal disease. Olmesartan 
medoxomil is a long-acting, well-tolerated, effective ARB that prevents or reverses endothelial 
dysfunction in animal models of atherosclerosis, hypertension, diabetes, nephropathy, and 
retinopathy. Olmesartan medoxomil, a prodrug of olmesartan approved for the treatment of 
hypertension, has been shown to ameliorate endothelial dysfunction in patients with hypertension 
or diabetes. In randomized studies, the drug reduces vascular inﬂ  ammation and the volume of 
large atherosclerotic plaques, increases the number of regenerative endothelial progenitor cells in 
the peripheral circulation, improves endothelium-dependent relaxation, and restores the normal 
resistance vessel morphology. Importantly, the impact of olmesartan medoxomil on endothelial 
dysfunction is thought to be independent of BP lowering.
Keywords: endothelial dysfunction, angiotensin receptor blocker, olmesartan medoxomil, 
hypertension, atherosclerosis
Introduction
Major advances in the treatment of cardiovascular disease (CVD) have been accompanied 
by the development of effective prevention strategies.1,2 In spite of these advances, CVD 
continues to be the leading cause of death in most countries in the world.3 The ongoing 
epidemic of obesity and increasing prevalence of diabetes mellitus and chronic kidney 
disease will further contribute to keeping diseases of the heart and blood vessels as the 
predominant cause of cardiovascular mortality.4–6
The common link between CVD risk factors such as hypertension, diabetes, and 
smoking is now recognized to be vascular endothelial dysfunction.7 Under normal 
circumstances, the vascular endothelium inﬂ  uences vessel tone and modulates structure, 
vessel permeability, adhesion and migration of inﬂ  ammatory cells, and hemostasis. 
In addition, the healthy vascular endothelium has a role in the prevention of oxidative 
damage. In contrast, endothelial dysfunction may be one of the earliest events initiating 
the cascade of maladaptive changes that contribute to target organ damage.8
Endothelial dysfunction of the coronary arteries is associated with an increased 
CVD risk.9 In addition to the conventional cardiovascular risk factors (coronary artery 
disease [CAD], age, and body mass index), markers of endothelial dysfunction were 
identiﬁ  ed as independent predictors of adverse events during a mean of 46 months Vascular Health and Risk Management 2009:5 302
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of follow-up in a prospective study in patients undergoing 
cardiac catheterization.9 Markers of endothelial dysfunc-
tion that predicted adverse outcomes included the change 
in coronary vascular resistance (ΔCVR) after intracoronary 
administration of acetylcholine and epicardial constriction 
with acetylcholine. Survival was improved in patients with 
the best microvascular responses after a 2-minute intracoro-
nary infusion of acetylcholine.9
Carotid artery intima-media thickness (IMT) is linearly 
correlated with the risk of myocardial infarction (MI) and 
stroke.10 A recent meta-analysis of eight studies showed that 
the risk of MI increased by approximately 25% and the risk 
of stroke increased by approximately 15% for each increase 
of one standard deviation in carotid artery IMT.10 Other 
studies have demonstrated reduced endothelial vasodilator 
capacity in siblings of hypertensive subjects.11,12 The common 
factor responsible for this phenomenon may be a novel 
polymorphism in the principal arginine transporter that 
accounts, at least in part, for the link between endothelial 
dysfunction, L-arginine, nitric oxide metabolism, and 
essential hypertension.13
Natural history of endothelial 
dysfunction
The development and progression of atherosclerosis is a 
result of inﬂ  ammatory processes including expression of 
markers of endothelial activation.14 For example, vascular 
cell adhesion molecule-1 facilitates the binding of monocytes 
and T-lymphocytes to vessel walls. A variety of cytokines 
and growth factors, such as macrophage colony-stimulating 
factor-1 (M-CSF-1) and transforming growth factor (TGF)-α 
and TGF-β, are released from inﬂ  ammatory lesions, recruit 
additional leucocytes, and stimulate proliferation of vascular 
smooth muscle cells.
As discussed elsewhere, the presence of monocytes 
in the intima is a characteristic of the early stages of 
plaque formation.15–18 Chemoattractant substances such as 
monocyte chemoattractant protein-1 (MCP-1) are generated 
by vascular inflammation and promote infiltration of 
monocytes into the intima. After inﬁ  ltrating the vascular 
endothelium, monocytes are transformed into tissue 
macrophages, which engulf lipid particles and become 
“foam cells”. Accumulation of foam cells gives rise to 
a visible fatty streak on the luminal surface of arteries. 
Work by the author and his associates ﬁ  rst established an 
obligatory role of angiotensin II (Ang II) in mediating the 
cascade of initiating events leading to the appearance of 
foam cells.15–18
Endothelial dysfunction involves accumulation of lipids, 
inﬂ  ammation, and proliferation of vascular smooth muscle 
cells. Recruitment of inﬂ  ammatory cells, proliferation of 
vascular smooth muscle, and accumulation of lipids by 
foam cells all contribute to thickening of the intima and 
the creation of an atherosclerotic plaque. Atherosclerosis 
occurs preferentially in areas of turbulent blood ﬂ  ow and 
low shear stress.19
Role of the renin-angiotensin-
aldosterone system (RAAS) 
in endothelial dysfunction
The renin-angiotensin-aldosterone system (RAAS) has a 
well-established role in the regulation of sodium levels, ﬂ  uid 
balance, and blood pressure (BP). Emerging evidence suggests 
that this system is also involved in the pathophysiology of 
type 2 diabetes mellitus and obesity.20–26
The classical view of the RAAS holds that the octapeptide 
Ang II is the terminal effector in this endocrine signaling 
pathway, and that upon binding to Ang II type 1 (AT1) 
receptors, vasoconstriction and sodium and water retention 
occur, along with mitogenic and proliferative effects on 
vascular endothelial and smooth muscle cells.27 There is 
evidence that Ang II is involved in pathologic inﬂ  ammation, 
and that it increases oxidative stress by regulating nicotinamide 
adenine dinucleotide phosphate (NADPH) levels, the principal 
source of reactive oxygen species (ROS) in the vasculature. 
Ang II also accelerates senescence of endothelial progenitor 
cells (EPCs).28 Senescence of EPCs is accelerated in patients 
with essential hypertension, and patients with CAD have 
fewer EPCs in peripheral blood.29
A seminal study assessing the role of Ang II in the 
development of atherosclerosis in primates ﬁ  rst documented a 
critical contribution of the renin-angiotensin system in the origin 
of fatty streak formation. In this study,30 the administration of 
the angiotensin receptor blocker (ARB), losartan, prevented the 
development of aortic fatty streak formation by a mechanism 
independent of BP. The central role of Ang II in endothelial 
dysfunction and atherosclerotic plaque formation is illustrated 
in Figure 1. Later studies in knockout mice conﬁ  rm that the 
AT1 receptor is involved in atherosclerosis. Apolipoprotein 
E knockout mice (ApoE-/-) have impaired endothelium-
dependent vasodilation, signiﬁ  cantly higher superoxide radical 
release rates, and develop marked atherosclerotic lesions when 
fed a high cholesterol diet. In contrast, AT1-/- mice have greatly 
reduced vascular oxidative stress, endothelial dysfunction, 
and atherosclerotic lesion formation irrespective of BP and 
plasma cholesterol levels. When ApoE-/- mice were crossbred Vascular Health and Risk Management 2009:5 303
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with AT1-/- mice, the resulting progeny (ApoE-/-, AT1-/-) had 
signiﬁ  cantly lower BP levels and superoxide release rates than 
ApoE-/- mice and did not develop atherosclerosis. These stud-
ies suggest a fundamental role of AT1 receptor activation in 
atherogenesis.31 In the pursuit of the mechanism accounting 
for the actions of Ang II in atherogenesis, we found that early 
activation of monocytes occurred through upregulation of the 
bone marrow renin-angiotensin system, whereby hypercholes-
terolemia stimulates the expression of bone marrow CD11b(+) 
receptors in monocytes.32–34
Over the last decade, it has become clear that the classical 
view of the RAAS is in need of revision. An additional RAAS 
effector that counterbalances the biological actions of Ang II 
has been isolated and characterized. This additional effector, 
the heptapeptide Ang-(1–7), is a fragment produced by 
hydrolysis of Ang I by several tissue-speciﬁ  c endopeptidases 
(prolyl oligopeptidase and thimet oligopeptidase in vascular 
endothelial and smooth muscle cells, and neprilysin in kidney 
cells) that bind to the G-protein-coupled mas receptor.35–38 
More recently, it has been shown that Ang-(1–7) is also 
produced by a homolog of angiotensin-converting enzyme 
(ACE), known as angiotensin-converting enzyme 2 (ACE2). 
ACE2 is a membrane-bound metallopeptidase that has a high 
speciﬁ  city for Ang II and acts to regulate the balance between 
Ang II and Ang-(1–7) in tissues via a mitogen-activated 
protein kinase phosphatase.27,39 Like Ang II, Ang-(1–7) is 
pleiotropic; however, in contrast to the effects of Ang II, 
Ang-(1–7) acts as a vasodilator and growth inhibitor and 
has been shown to counter-regulate the effects of Ang II in 
human endothelial cells.40 The role of Ang-(1–7) in CVD and 
hypertension is shown in Table 1.
Disruption of ACE2 resulted in marked increases in 
Ang II levels and cardiac contractility defects in rat models 
of hypertension.41 In contrast, ablation of ACE in ACE2-
deﬁ  cient mice restored the normal cardiac phenotype.41 These 
data demonstrate that a counter-regulatory balance exists 
between the two arms of the RAAS, as illustrated in Figure 2.
As proposed by Ferrario,42 under normal physiological 
conditions, both the ACE/Ang II and the ACE2/Ang(1–7) 
axes of the RAAS strike a balance between proliferative and 
antiproliferative effects. However, when a physiological 
imbalance occurs as a result of a pathological process, such 
as increased activity of the ACE/Ang II/AT1 receptor axis, 
the failure of compensation by the opposing axis favors 
hypertension and consequent cardiovascular remodeling.
Drugs that target and block the effects of Ang II would 
be expected to prevent or reverse endothelial dysfunction and 
improve long-term morbidity and mortality outcomes in a broad 
spectrum of patients. This is, indeed, the case. Three classes 
of agents, ACE inhibitors, ARBs, and, most recently, direct 
renin inhibitors (DRIs), have been developed to speciﬁ  cally 
target the RAAS. Most experience has been gained with ACE 
inhibitors and ARBs, which are widely approved and used 
for the treatment of hypertension and prevention of CVD, 
although a recent study showed that aliskiren resulted in striking 
reductions of atherosclerosis in fat-fed low-density lipoprotein 
(LDL) receptor-deﬁ  cient (LDLr-/-) mice.43
ARBs selectively target the AT1 receptor and have a well-
established role in the management of hypertension. Drugs in 
this class have been shown to improve outcomes in patients 
with hypertension, ventricular hypertrophy, diabetes mellitus, 
renal disease, and congestive heart failure.44–51
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Figure 1 Atherosclerotic plaque formation in relationship to Ang II. Reprinted from the Lancet, 369, Schmeider RE, Hilgers KF, Schlaich MP. Renin-angiotensin system and 
cardiovascular risk, 1208–1219.109 Copyright © 2007, with permission from Elsevier.
Abbreviations: ICAM-1, intercellular adhesion molecule-1; LDL, low-density lipoprotein; LOX-1, lectin-like oxidized low-density lipoprotein receptor-1; MCP-1, monocyte 
chemoattractant protein-1; MMP, matrix metalloproteinase; NADPH, nicotinamide adenine dinucleotide phosphate; NRB, norbormide; PAI-1, plasminogen activator inhibitor-1; 
TNF, tumor necrosis factor;   VCAM-1, vascular cell adhesion molecule-1;   VSMCs, vascular smooth muscle cells.Vascular Health and Risk Management 2009:5 304
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Within the ARB class, olmesartan medoxomil is a 
long-acting Ang II antagonist approved for the treatment of 
mild to severe hypertension, alone or in combination with 
other agents. In addition to producing sustained reductions 
in BP, the drug corrects the underlying defects that lead to 
endothelial dysfunction in animal models of CVD, and in 
patients with CVD or hypertension. Moreover, the beneﬁ  cial 
effects of the drug on endothelial dysfunction have been shown 
to complement those of the 3-hydroxy-3-methyl-glutaryl 
coenzyme A (HMG-CoA) reductase inhibitors. Intriguing 
evidence suggests that olmesartan upregulates cardiac 
and vascular expression of ACE2, which leads to greater 
conversion of Ang II into the vasodilator and anti-proliferative 
peptide Ang-(1–7).27,30,39,42,52–62 The purpose of this paper is to 
review the extensive literature on the effects of olmesartan 
medoxomil on endothelial dysfunction, both in humans and 
animal models.
Studies in humans
Olmesartan medoxomil produces broad-based improvements 
in endothelial dysfunction in patients with hypertension. 
The drug reduces vascular micro-inﬂ  ammation, decreases 
the volume of large atherosclerotic plaques, improves 
endothelium-dependent relaxation, and restores normal 
resistance vessel morphology. An overview of beneﬁ  cial 
effects of olmesartan medoxomil on endothelial function in 
humans is provided in Table 2.
Effect of olmesartan medoxomil 
on markers of vascular inﬂ  ammation: 
the EUTOPIA study
Olmesartan medoxomil significantly reduced vascular 
inﬂ  ammation in patients with hypertension in the European 
Trial on Olmesartan and Pravastatin in Inﬂ  ammation and 
Atherosclerosis (EUTOPIA) study. EUTOPIA was a 
rando  mized, placebo-controlled, multicenter study in 199 
patients with hypertension and vascular micro-inﬂ  ammation. 
Vascular micro-inﬂ  ammation was deﬁ  ned as the presence 
of any diagnosed atherosclerotic disease (eg, coronary or 
peripheral arterial disease), type 2 diabetes mellitus, and/or 
an LDL-cholesterol level between 3.89 and 6.48 mmol/L 
(152–253 mg/dL).63 In addition to hypertension (seated 
diastolic BP [SeDBP] of 95 to 110 mmHg), eligible patients 
were required to have a high-sensitivity C-reactive protein 
(hsCRP) concentration 3 mg/L but 20 mg/L, and detect-
able serum levels of interleukin-6 (IL-6) and inter  cellular 
adhesion molecule-1 (ICAM-1).63 Patients were randomized to 
12 weeks of treatment with olmesartan medoxomil 20 mg/day 
Table 1 Ang-(1–7) in cardiovascular disease and hypertension
Animal studies
  Blockade of Ang-(1–7) dose-dependently ↑ arterial BP in salt-restricted rats89
  Intracerebroventricular administration of anti-Ang-(1–7) antibodies ↑ BP in rats90
  Ang-(1–7) augments baroreceptor reﬂ  ex control of HR at the nucleus of the solitary tract91
  Ang-(1–7) is cardioprotective in heart failure in rats induced by Ang II92
  Ang-(1–7) protects against ischemic injury and arrhythmia in isolated rat hearts93,94
  Ang-(1–7) dilates afferent arterioles, ↑ GFR and induces natriuresis and diuresis95–97
 Ang-(1–7)  ↓ neointimal proliferation after vascular injury in rat carotid arteries52
 Ang-(1–7)  ↓ Ang II-induced protein synthesis in cardiomyocytes56
 Ang-(1–7)  ↓ myocyte surface area after MI induced by coronary artery ligation in rats98
  Olmesartan, but not atenolol, ↑ Ang I,   Ang II, and Ang-(1–7) in SHR57
  Olmesartan, but not atenolol or hydralazine, ↑ ACE2 and Ang-(1–7) and improved remodeling of the aorta in SHR55
  Olmesartan and losartan ↑ ACE2 mRNA in non-infarcted ventricular tissue in rats53
 Olmesartan  ↑ cardiac ACE2 expression in stroke-prone SHR58
 Olmesartan  ↑ ACE2 immunostaining in neointima of injured carotid arteries in SHR62
  Cardiac ACE2 metabolizes Ang II to Ang-(1–7) in the hearts of hypertensive rats59
Human studies
  Plasma and urinary Ang-(1–7) levels are ↓ in untreated hypertensive patients99
  Plasma and urinary Ang-(1–7) ↑ when BP ↓ with agents that modulate the RAAS100–102
Abbreviations: ACE, angiotensin-converting enzyme; Ang, angiotensin; BP, blood pressure; GFR, glomerular ﬁ  ltration rate; HR, hypertensive rats; MI, myocardial infarction; 
mRNA, messenger ribonucleic acid; RAAS, renin-angiotensin-aldosterone system; SHR, spontaneously hypertensive rats.Vascular Health and Risk Management 2009:5 305
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or placebo. Hydrochlorothiazide 12.5 or 25 mg/day could 
be added for patients whose SeDBP remained 90 mmHg. 
After 6 weeks of double-blind treatment, all patients started 
treatment with the HMG-CoA reductase inhibitor pravastatin 
20 mg/day and continued treatment for the remainder of the 
study.63 The ﬁ  nal full analysis set comprised 100 patients in 
the olmesartan medoxomil and 99 patients in the placebo 
treatment groups.
The primary outcome was the impact of olmesartan 
medoxomil (alone or in combination with pravastatin) on a 
panel of anti-inﬂ  ammatory measures: hsCRP, high sensitivity 
tumor necrosis factor-α (hsTNF-α), IL-6, ICAM-1, and 
MCP-1.63 Olmesartan medoxomil produced significant 
reductions from baseline in hsCRP, hsTNF-α, IL-6, and 
MCP-1 (all comparisons p  0.05 vs baseline), but not 
ICAM-1, after 6 and 12 weeks of treatment. In contrast, there 
were no statistically signiﬁ  cant reductions from baseline in any 
inﬂ  ammatory markers in patients treated with placebo, with 
the exception of IL-6 at Week 6 (but not at Week 12).63 The 
difference in hsTNF-α between olmesartan medoxomil and 
placebo recipients at Week 12 was statistically signiﬁ  cant.
There were no signiﬁ  cant changes in the serum lipid proﬁ  le 
between baseline and Week 6 in recipients of olmesartan 
medoxomil or placebo. As expected, the addition of pravastatin 
produced significant reductions in total cholesterol and 
LDL cholesterol between Week 6 and Week 12 of treatment in 
both groups.63 Systolic BP (SBP)/DBP decreased signiﬁ  cantly 
compared with baseline in both treatment groups, with signiﬁ  -
cantly greater reductions achieved with olmesartan medoxomil 
than placebo at all time points with the exception of SBP at 
Week 12.63
Effect of olmesartan medoxomil on EPCs 
in patients with type 2 diabetes mellitus
ARBs increase the number of regenerative EPCs in 
peripheral blood of patients with type 2 diabetes mellitus, 
a condition associated with endothelial dysfunction.64 In a 
randomized, double-blind, placebo-controlled study, before 
treatment with olmesartan medoxomil, the number of EPCs 
was signiﬁ  cantly lower in 18 patients with type 2 diabetes 
mellitus and hypertension compared with 38 age-matched 
healthy volunteers.64 After 12 weeks of treatment with 
olmesartan medoxomil 40 mg/day (n = 9), the number of 
circulating EPCs increased signiﬁ  cantly in patients with 
type 2 diabetes mellitus (from 231 to 465 per high power 
ﬁ  eld width, p  0.05 vs placebo). There was no change in 
the number of CD34+ hematopoietic progenitor cells after 












Figure 2 The renin-angiotensin-aldosterone system. Reproduced with permission from Trask AJ, Ferrario CM. Angiotensin-(1–7): pharmacology and new perspectives in 
cardiovascular treatments. Cardiovasc Drug Rev. 2007;25(2):162–174.60 Copyright © 2007. Blackwell Publishing.
Abbreviations: ACE, angiotensin-converting enzyme; Ang, angiotensin; AT1R, angiotensin type 1 receptor; AT2R, angiotensin type 2 receptor; NEP, neprilysin; POP, prolyl 
oligopeptidase; TOP, thimet oligopeptidase.Vascular Health and Risk Management 2009:5 306
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Effect of olmesartan medoxomil 
on atherosclerotic lesions: the MORE study
The results of the Multicentre, Olmesartan, atherosclerosis 
Regression Evaluation (MORE) study suggest that 
olmesartan medoxomil reduces the volume of larger 
atherosclerotic plaques in patients with hypertension, 
independent of BP reduction.65 After 2 years of treatment, 
there was no statistically signiﬁ  cant difference between 
treatment groups in the IMT of the common carotid artery 
(CC-IMT), as determined by 2-dimensional ultrasound, 
the primary efﬁ  cacy outcome in the trial. Among patients 
randomized to olmesartan medoxomil (20–40 mg/day, 
n = 78), the mean change in CC-IMT was –0.090 mm, 
and among those randomized to atenolol (50–100 mg/day, 
n = 77), the mean reduction in CC-IMT was –0.082 mm. 
The overall mean change in plaque volume, as determined 
by 3-dimensional ultrasound, was –4.4 μL in patients 
randomized to olmesartan medoxomil and +0.1 μL in 
patients randomized to atenolol, although the difference 
was not statistically signiﬁ  cant. However, the reduction 
in plaque volume was signiﬁ  cantly greater in recipients of 
olmesartan medoxomil (–11.5 μL) (p = 0.023 vs atenolol) 
than atenolol (+0.6 μL) when the analysis was restricted 
to patients with a baseline plaque volume greater than 
or equal to the median value (33.7 μL). There was no 
statistically signiﬁ  cant difference in mean SBP/DBP at 
baseline (158/96 vs 157/96 mmHg, respectively) or in the 
mean reduction in SBP/DBP after 2 years of treatment 
(–25/–15 vs –22/–14 mmHg, respectively) between 
patients randomized to olmesartan medoxomil or atenolol. 
There was a higher proportion of men (73% vs 50% in 
the olmesartan medoxomil group), more current smokers 
(38% vs 31% in the olmesartan medoxomil group), and 
more patients with a history of CVD (14% vs 9% in the 
olmesartan medoxomil group) among those randomized to 
atenolol.65 It is possible that technical limitations in terms 
of resolving differences in the volume of small plaques by 
3-dimensional ultrasound sonography accounted for the 
failure of observing differences in plaque regression.
Effect of olmesartan medoxomil 
on endothelium-dependent vasodilation
Olmesartan medoxomil improved endothelium-dependent 
coronary artery dilation in patients with hypertension in a 
randomized study in 26 patients with untreated hypertension 
(BP  140/90 mmHg). After 12 weeks, the mean decrease 
in SBP was similar in patients randomized to olmesartan 
medoxomil (n = 13; –28.7 mmHg) or amlodipine (n = 13; 
–26.7 mmHg).66 However, there was a signiﬁ  cant increase of 
the delta change in corrected myocardial blood ﬂ  ow (before 
vs after treatment p  0.001) and a signiﬁ  cant decrease in the 
ΔCVR (before vs after treatment p  0.01) from rest after a 
cold pressor test as measured by positron emission tomog-
raphy among patients treated with olmesartan medoxomil.66 
In contrast, 12 weeks of treatment with amlodipine had no 
effect on either parameter.66
Table 2 Overview of beneﬁ  cial effects of olmesartan medoxomil on endothelial function in humans
Effects of olmesartan medoxomil in humans with hypertension55–59
Reduce vascular micro-inﬂ  ammation
↓ hsCRP (vs baseline)
↓ hsTNF-α (vs baseline)
↓ IL-6 (vs baseline)
↓ MCP-1 (vs baseline)
↑ number of regenerative EPCs in peripheral blood
↓ volume of large atherosclerotic plaques (vs atenolol)
Improved endothelium-dependent coronary artery dilation
↑ change in corrected myocardial blood ﬂ  ow
↓ change in coronary vascular resistance from rest to after a cold pressor test as measured by positron emission tomography
Restores normal resistance vessel morphology in patients with hypertension
↓ mean augmentation index (augmentation pressure/pulse pressure), a surrogate measure of vascular compliance
↓ wall width, media cross-sectional area, and wall-to-lumen ratio of resistance arteries in gluteal subcutaneous biopsies
Abbreviations: EPC, endothelial progenitor cells; hsCRP, high-sensitivity C-reactive protein; hsTNF, high-sensitivity tumor necrosis factor; IL-6, interleukin-6; MCP-1, mono-
cyte chemoattractant protein-1.Vascular Health and Risk Management 2009:5 307
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Among patients treated with olmesartan medoxomil, there 
was also a signiﬁ  cant negative correlation between changes 
in serum superoxide dismutase (SOD) activity and CVR.58
The study by Naya et al66 provides evidence that treatment 
with an ARB (olmesartan medoxomil) but not a calcium 
channel blocker (amlodipine) has a salutary effect on the 
coronary microcirculation and improves endothelium-depen-
dent coronary dilation independent of BP lowering.66
Effect of olmesartan medoxomil on vessel 
morphology: the VIOS study67,68
The objective of VIOS (Vascular Improvement with Olmesartan 
medoxomil Study) was to examine the impact of olmesartan 
medoxomil on vascular remodeling in nondiabetic patients with 
stage 1 hypertension as evaluated in the ofﬁ  ce setting. A total of 
100 patients were randomized to 12 months of treatment with 
either olmesartan medoxomil 20 mg/day or atenolol 50 mg/day. 
The dosage of either agent was doubled to achieve optimal BP 
control, and hydrochlorothiazide, amlodipine, or hydralazine 
could be added to ongoing therapy.67 As a result of this study 
design, the mean reduction in BP was not statistically different 
between treatment groups at Week 12, 28, or 52 of treatment.
The mean augmentation index (augmentation pressure/
pulse pressure), a surrogate measure of vascular compliance, 
decreased signiﬁ  cantly between baseline and the end of 
treatment in olmesartan medoxomil recipients, but was 
unchanged among atenolol recipients. Signiﬁ  cant decreases 
in central aortic pressure were also documented, with no 
differences between the two treatment groups.67 On the other 
hand, prior to initiation of the treatment period, measures of 
central aortic pressure in the overall group of patients averaged 
131 ± 16 mmHg, a value that is within the range established 
for prehypertension by the Seventh Report of the Joint 
National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure (JNC 7) classiﬁ  cation.
Before initiation of treatment, the wall width (WW), media 
cross sectional area (MCSA), and wall-to-lumen (W/L) ratio 
of resistance arteries in gluteal subcutaneous biopsies were 
all signiﬁ  cantly higher in a subgroup of 55 patients with 
hypertension than in a parallel group of 11 normotensive 
volunteers.67 At baseline, these dimensions were similar in 
hypertensive patients randomized to olmesartan medoxomil 
(n = 27) or atenolol (n = 22); however, after 12 months of treat-
ment with olmesartan medoxomil, but not with atenolol, there 
was a signiﬁ  cant decrease in all of these arteriolar dimensions 
(p  0.01 vs baseline). The mean W/L ratio in arteries 
from patients receiving olmesartan medoxomil therapy was 
signiﬁ  cantly reduced after 1 year of treatment compared with 
baseline (11.1% ± 0.5 vs 14.9% ± 0.8, respectively; p  0.01), 
whereas the mean W/L ratio in arteries from atenolol-treated 
patients was not signiﬁ  cantly decreased (15.5% vs 16.0%, 
respectively; p  0.05). The mean W/L ratio in olmesartan 
medoxomil recipients (11.1%) was similar to that in normo-
tensive controls (11.0%) after 1 year of treatment. The VIOS 
trial demonstrated that 1 year of treatment with olmesartan 
medoxomil restored the normal resistance vessel morphology 
in stage 1 hypertension independent of BP lowering.67
Studies in animals
Olmesartan has been shown to reduce oxidative stress and 
endothelial inﬂ  ammation, and to prevent or reverse the 
formation of atherosclerotic lesions and vascular remodeling 
processes in a variety of animal models of atherosclerosis. 
The drug has also been shown to have renoprotective effects 
in animal models of kidney disease and retinoprotective 
effects in an animal model of retinopathy.
Diabetes, insulin resistance, and metabolic 
syndrome animal models
Mice fed a high fat diet have increased oxidative stress 
in cardiac, vascular, and hepatic tissue.69 Olmesartan 
5 mg/kg/day markedly suppressed cardiac inﬂ  ammation and 
ﬁ  brosis, ameliorated endothelial dysfunction, and retarded 
vascular remodeling in an animal model of diabetes.69 The 
drug also prevented hepatic steatosis, halted progression of 
hepatic ﬁ  brosis, and suppressed the disruption in vascular 
endothelial NO synthase (eNOS) dimer. The beneﬁ  cial 
effects of olmesartan were associated with a decrease in 
apoptosis signal regulating kinase-1 (ASK-1). ROS acti-
vate ASK-1, which, in turn, has been shown to be involved 
in Ang II-induced cardiac hypertrophy and remodeling.70 
Interestingly, hydralazine lowered BP in the same strain 
of diabetic mice, but, unlike olmesartan, had no effect on 
cardiac remodeling, vascular endothelial function, or hepatic 
ﬁ  brosis.69 Moreover, olmesartan had no effect on any of these 
parameters in ASK-1-deﬁ  cient mice. The results of the study 
suggest that Ang II plays a central role in cardiovascular 
remodeling and endothelial dysfunction in the setting of 
diabetes, and that olmesartan prevents vascular remodeling, 
in part, by attenuating the generation of ROS.69
Models of hypertension
Treatment with olmesartan 15 mg/kg/day and enalapril 
25 mg/kg/day from age 8 weeks to age 12 weeks signiﬁ  cantly 
decreased the left ventricular weight:body weight ratio and 
normalized cardiac collagen content and the media:lumen Vascular Health and Risk Management 2009:5 308
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ratio in spontaneously hypertensive rats (SHR). Signiﬁ  cant 
improvements in aortic collagen content were also obtained 
with a lower dose of olmesartan (1 mg/kg/day) but not 
enalapril (2 mg/kg/day).71
In another study in SHR that served as the rationale for 
the VIOS study (see above67), olmesartan 10 mg/kg/day 
produced a greater reduction in the arteriolar W/L ratio than 
atenolol after 8 weeks of treatment, despite similar reductions 
in BP.57 Treatment with olmesartan signiﬁ  cantly increased 
lumen diameter and signiﬁ  cantly decreased WW and the 
W/L ratio of mesenteric arteries compared with control 
SHR. The improvement in W/L ratio was also signiﬁ  cantly 
greater than that achieved with atenolol. Treatment with 
atenolol also decreased WW and the W/L ratio but did not 
signiﬁ  cantly alter the lumen diameter. The lumen diameter 
was significantly greater in olmesartan-treated animals 
than in control rats when exposed to luminal pressures 
ranging from 20 mmHg to 100 mmHg. Atenolol-treated 
animals did not differ from control animals in this respect. 
The heart weight:body weight ratio, a measure of cardiac 
hypertrophy, was signiﬁ  cantly decreased in animals treated 
with olmesartan, but not with atenolol. The results of this 
study are consistent with those of the 1-year-long VIOS trial 
in humans and demonstrate that treatment with olmesartan 
can restore resistance vessel morphology after pathological 
changes have occurred.
Olmesartan reduced the production of ROS, suppressed 
tissue inﬁ  ltration of macrophages, and prevented ventricular 
hypertrophy and ﬁ  brosis in hypertensive Dahl salt-sensitive 
rats with advanced heart failure who were administered olm-
esartan from age 17 weeks to age 20 weeks.72 The addition 
of olmesartan 0.3 mg/kg/day to ongoing treatment with an 
ACE inhibitor (temocapril 0.2 mg/kg/day) produced further 
reductions in 4-hydroxy-2-nonenal-modiﬁ  ed protein levels, 
a lipid peroxidation product and marker of ROS generation, 
in addition to those produced by the ACE inhibitor alone.72 
The beneﬁ  cial effects of olmesartan in these models may be 
attributable, in part, to upregulation of ACE2, which results 
in increased Ang-(1–7) levels.53,61 For example, Yokoyama 
et al57 detected elevated concentrations of Ang I, Ang II, 
and Ang-(1–7) in SHR treated with olmesartan, but not 
atenolol. In another study in SHR, treatment with olmesartan 
at a dose of 10 mg/kg/day increased ACE2 and Ang-(1–7) 
production and was associated with improved vascular 
remodeling of the aorta.55 In this study, olmesartan produced 
a ﬁ  ve-fold increase in ACE2 mRNA in the thoracic aorta. In 
contrast, neither atenolol nor hydralazine had an impact on 
ACE2 mRNA expression. Olmesartan selectively reduced 
the media:lumen ratio and media thickness of the thoracic 
aorta but not the carotid arteries in this model. These data 
demonstrate that BP-independent vascular remodeling 
is regulated by AT1 receptors and can be modulated by 
treatment with an ARB.55
In a subsequent experiment, treatment with olmesartan 
10 mg/kg/day for 14 days produced a 61% reduction in the 
cross-sectional area of the neointima of balloon-injured carotid 
arteries in SHR.62 The intensity of ACE2 immunostaining in 
tissue taken from the injured artery was signiﬁ  cantly greater 
in olmesartan-treated animals compared with vehicle-treated 
controls. There was no change in neointima thickness or 
immunostaining intensity in the uninjured contralateral carotid 
artery, which suggests that changes in ACE2 expression are 
regulated by a factor other than BP.62
Coronary artery ligation-induced MI in normotensive 
rats results in left ventricular dysfunction and left ventricular 
hypertrophy, and is associated with increased plasma Ang I, 
Ang II, angiotensin-(1–7), elevated serum aldosterone, and 
reduced AT-1a receptor mRNA.53 Blockade of AT-1a receptors 
with an ARB (losartan or olmesartan) for 28 days attenuated 
cardiac hypertrophy, reduced aldosterone levels, and was 
associated with further increases in Ang levels. Olmesartan 
improved contractility; losartan did not. Both ARBs produced 
a three-fold increase in ACE2 mRNA levels and downregu-
lated AT-1a receptor expression in non-infarcted ventricular 
tissue.53 The beneﬁ  cial effects of ARB treatment in this model 
were independent of effects of BP and infarct size. The results 
suggest that upregulation of ACE2 and increased conversion 
of Ang II to Ang-(1–7) counterbalances the vasopressor 
effects resulting from the ACE-mediated conversion of 
Ang I to Ang II.
Animal models of atherosclerosis
Hypercholesterolemia-induced atherosclerosis in cynomolgus 
monkeys (Macaca fascicularis) is similar to that in humans. 
When maintained on a high cholesterol diet, monkeys develop 
fatty aortic streaks that can be detected by intravascular 
ultrasonography; increased levels of TGF-β1, ICAM-1, and 
M-CSF; and accumulations of macrophages in the intima, as 
evidenced by increased binding of speciﬁ  c antibodies in aortic 
cross sections.30,73,74 Treatment with olmesartan 10 mg/kg/day 
maintained TGF-β1, ICAM-1, and M-CSF levels similar to 
those in control monkeys fed a normal diet; signiﬁ  cantly 
reduced the accumulation of macrophages in the intima; 
signiﬁ  cantly reduced the extent of lipid deposition in the aorta; 
and signiﬁ  cantly reduced the atherosclerotic intima area, and 
intima area:media area ratio of the aorta.Vascular Health and Risk Management 2009:5 309
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In a subsequent 12-month study in the same monkey 
model of atherosclerosis,74 treatment with olmesartan 
3 mg/kg/day signiﬁ  cantly reduced serum levels of MCP-1, 
an inﬂ  ammatory marker, compared with cholesterol-fed 
monkeys; signiﬁ  cantly reduced the intima volume:total 
volume ratio of the thoracic aorta; and produced signiﬁ  cant 
regression in the size of existing atherosclerotic lesions as 
indicated by the atherosclerotic area:total surface area of the 
aorta. Importantly, all of the effects attributable to olmesartan 
in these studies occurred without signiﬁ  cant effects on 
BP or total cholesterol, LDL-cholesterol, or high-density 
lipoprotein-cholesterol levels.73,74
In Watanabe heritable hyperlipidemic rabbits, the 
combination of olmesartan and pravastatin had complementary 
inhibitory effects on atherosclerotic lesions. Olmesartan 
0.5 mg/kg/day and pravastatin 25 mg/kg/day produced 
signiﬁ  cant reductions in BP and blood cholesterol levels 
that were accompanied by signiﬁ  cant reductions in the 
surface area and thickness of atherosclerotic lesions and 
in aortic cholesterol content. The anti-atherosclerotic 
effects of the two drugs in combination were signiﬁ  cantly 
greater than those produced by monotherapy with either 
agent.75 Immunohistochemical staining of cross sections of 
aortic tissue showed that both drugs inhibited macrophage 
inﬁ  ltration, that pravastatin inhibited lipid deposition, and 
that olmesartan reduced MCP-1 expression and formation 
of Nε–(carboxymethyl)lysine protein adducts, a marker of 
oxidative stress.75
The combination of olmesartan and pravastatin produced 
additive improvements in left ventricular remodeling 
in rats with MI induced by ligation of the left anterior 
descending coronary artery. When administered alone, 
both drugs decreased cardiomyocyte size; however, the 
magnitude of the improvement was greater when the two 
drugs were co-administered. Treatment with the two drugs 
also downregulated left ventricular atrial natriuretic peptide 
mRNA. The effects on cardiomyocyte hypertrophy were 
dose-dependent.75
The combination of olmesartan and pravastatin also 
signiﬁ  cantly reduced the progression of atherosclerosis in 
ApoE*3Leiden transgenic mice, which develop a human-
like lipoprotein proﬁ  le when fed a cholesterol-rich diet. The 
number and extent of atherogenic lesions and the number 
of macrophages and T lymphocytes per cross section was 
signiﬁ  cantly reduced in mice treated with the combination 
compared with controls. When administered alone or in 
combination with pravastatin, olmesartan reduced the quantity 
of macrophages in lesions compared with control.76
The combination of olmesartan and pravastatin improved 
endothelial function in salt-loaded Dahl salt-sensitive 
hypertensive rats.77 Vascular endothelium-dependent 
relaxation to acetylcholine, coronary arterial remodeling, and 
eNOS activity were all signiﬁ  cantly improved after 4 weeks 
of treatment with olmesartan 0.5 mg/kg/day plus pravastatin 
100 mg/kg/day. Olmesartan prevented disruption of 
vascular eNOS dimers and downregulation of dihydrofolate 
reductase to a greater extent than pravastatin; conversely, 
Akt phosphorylation was enhanced by pravastatin, but not 
by olmesartan medoxomil.
Studies in ApoE knockout mice
ApoE knockout mice are predisposed to develop atheroscle-
rosis. When fed a high cholesterol diet, these mice develop 
marked atherosclerotic lesions in the proximal aorta and 
exhibit signs of oxidative stress (increased staining for 
NADPH oxidase, an enzyme that produces ROS).78 At a dose 
of 3 mg/kg/day, olmesartan signiﬁ  cantly inhibited NADPH 
oxidase activity, decreased superoxide production, reduced 
the formation of atherosclerotic lesions, and inhibited lipid 
deposition.78 In another study in which apoE knockout mice 
were fed either a high cholesterol or normal diet for 25 weeks, 
treatment with olmesartan 10 mg/kg/day produced signiﬁ  cant 
reductions in the surface area of aortic lesions and the cross-
sectional area of aortic valves in both groups of mice.79
Renoprotective effects
Olmesartan has been shown to significantly improve 
urinary protein and β2-microglobulin excretion, ameliorate 
glomerular sclerosis and tubulointerstitial injury, and to 
signiﬁ  cantly reduce staining for TGF-β, vascular endothelial 
growth factor, and type IV collagen in glomeruli of diabetic 
rats.80 SHR have enhanced intrarenal angiotensinogen 
production that contributes to increased Ang II levels and 
leads to hypertension and renal injury. Olmesartan reduced 
the urinary excretion rate of total protein, prevented 
glomerular sclerosis, interstitial expansion, and reduced the 
numbers of monocytes/macrophages in the interstitium or 
glomeruli of SHR. The drug also reduced angiotensinogen 
mRNA and protein levels in the kidney cortex, as measured 
by real-time PCR.81 In corpulent SHR, treatment with the 
drug significantly reduced BP and kidney pentosidine 
content (which is correlated with proteinuria) and reduced 
histologic renal damage and proteinuria.82 In another 
study in SHR, olmesartan, but not nifedipine or atenolol, 
signiﬁ  cantly reduced proteinuria and prevented glomerular 
and tubulointerstitial damage (mesangial activation, podocyte Vascular Health and Risk Management 2009:5 310
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injury, tubulointerstitial injury, and inflammatory cell 
inﬁ  ltration). The drug also selectively prevented abnormal 
iron deposition in the interstitium, corrected chronic hypoxia, 
reduced expression of heme oxygenase and p47phox (a subunit 
of NADPH oxidase), and inhibited pentosidine formation in 
this animal model. The unique renoprotective properties of 
olmesartan were independent of BP reductions and appeared 
to be attributable to decreased oxidative stress, correction of 
chronic hypoxia, and inhibition of advanced glycation end 
product formation, and of abnormal iron deposition.83
Retinoprotective effects
Olmesartan has been shown to have beneﬁ  cial effects in 
several animal models of early and late stage retinopathy. 
The drug prevented elongation of oscillatory potential peaks 
in a dose-dependent manner in diabetic stroke-prone SHR. 
In mice with oxygen-induced retinopathy, the drug signiﬁ  -
cantly prevented retinal neovascularization at a dosage of 
1 mg/kg/day. Plasma concentrations of olmesartan in these 
experiments were comparable to the in vitro IC50 value of 
the AT1 receptor.84
Miscellaneous effects of olmesartan
Olmesartan has been shown to have antiproliferative effects 
in animal models of CVD. Olmesartan signiﬁ  cantly reduced 
endothelial inﬂ  ammatory events in a mouse model of vascular 
injury that involves the placement of a polyethylene cuff 
around the femoral artery.85 At a dose of 3 mg/kg/day, the 
drug signiﬁ  cantly reduced TNF-α and MCP-1 levels, which 
were accompanied by decreased neointima formation and 
vascular smooth muscle proliferation. In another study that 
used the same model of endothelial inﬂ  ammation, olmesartan 
reduced the number of bromodeoxyuridine-positive vascular 
smooth muscle cells present in the media and neointima, and 
prevented phosphorylation of extracellular signal-regulated 
kinase (ERK, an enzyme associated with progression of 
ﬁ  brosis and cell proliferation) and signal transducer and acti-
vator of transcription, all of which indicate that cell division 
in inflammatory lesions is attenuated by olmesartan.86 
Treatment with the drug also signiﬁ  cantly reduced the rate 
of DNA synthesis in vascular smooth muscle cells in vitro, 
as indicated by incorporation of [3H]-thymidine, and blocked 
activation of ERK.87
Endothelium-dependent relaxation of the aorta of 12-month-
old Wistar-Kyoto rats is markedly impaired compared with 
those of 3-month-old rats.88 Thus, aged rats serve as a model 
for age-related endothelial dysfunction. Tiron, a superoxide 
scavenger, partially improved endothelium-dependent 
relaxation in this model, suggesting involvement of super-
oxide. Treatment of aged rats with olmesartan 5 mg/kg/day 
for 2 weeks signiﬁ  cantly reduced superoxide production. 
Endothelium-dependent relaxation also improved in aged rats 
after long-term treatment with olmesartan or temocapril, but 
not cerivastatin or hydralazine. Indomethacin also improved 
endothelium-dependent relaxation when administered 
alone, but not after treatment with olmesartan or temocapril. 
Cyclooxygenase (COX)-2 protein expression and superoxide 
production were increased in the aortas of aged rats, but were 
attenuated by olmesartan and temocapril. These results suggest 
that inhibition of the RAAS corrects age-related endothelial 
dysfunction, in part, by inhibiting synthesis of COX-2-derived 
vasoconstricting factors and superoxide anions.88
Summary and conclusions
Endothelial dysfunction is the common link between CVD 
risk factors and is one of the earliest events in the cascade 
of changes that results in target organ damage in patients 
with hypertension. It has been shown that coronary artery 
endothelial dysfunction is associated with increased CVD 
risk, and increased carotid artery IMT is predictive of MI 
and stroke. The large arteries in hypertensive patients are 
thicker and stiffer than those in normotensive individuals; 
thus, reversal of the underlying processes that cause these 
structural changes and normalization of vessel wall dimen-
sions should be a goal of antihypertensive therapy.
Ang II is a potent vasoconstrictor, which promotes sodium 
and ﬂ  uid retention and has mitogenic and proliferative effects 
on vascular endothelial and smooth muscle cells. Under normal 
physiological conditions, these effects are counterbalanced 
by Ang-(1–7). In contrast, under pathological conditions, 
the effects of Ang II become predominant and endothelial 
dysfunction results. ARBs correct the pathological imbalance 
in the RAAS, in part, by augmenting the activity of the 
ACE2/Ang-(1–7) axis.42,54
While it would be expected that all Ang II receptor blockers 
share similar characteristics in terms of the mechanisms of 
action, both past89 and emerging data suggest that this may 
not be the case. A systematic review, performed to identify 
the factors that determine the antihypertensive activity of the 
ARBs using 24-hour ambulatory BP monitoring data from 
35 studies, showed the greatest reductions in both SBP and 
DBP being seen with olmesartan medoxomil.90 Studies of 
the pharmacological characteristics of olmesartan provide 
support for the clinical ﬁ  ndings. In vitro studies of guinea 
pig aorta showed that olmesartan inhibited Ang II-induced 
contraction with a potency 160, 3.4, and 1.2 times greater than Vascular Health and Risk Management 2009:5 311
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losartan, EXP-3174, and candesartan, respectively.91,92 Since 
the effects of olmesartan lasted for more than 90 minutes after 
the drug was removed, these data showed that olmesartan acts 
as a speciﬁ  c and insurmountable antagonist of Ang II-induced 
vessel contraction. This means that even in the presence 
of high quantities of Ang II, the physiological response to 
this mediator shall remain low, whereas a surmountable 
antagonism (fast reversible binding, short-lasting inhibition) 
would lead to a full physiological response, even if in the 
presence of higher doses of the agonist peptide. Additional 
comparative studies of the pharmacokinetic characteristics 
of olmesartan showed that the IC50 values for olmesartan 
receptor binding is eight times greater than telmisartan and 
474 times more potent than losartan.93 Another interesting 
feature of olmesartan is its ability to inhibit ACE. This 
evidence comes from the observation that treatment with 
olmesartan in stroke-prone SHR decreases plasma Ang II 
levels while concomitantly elevating plasma Ang-(1–7) 
levels through increase in ACE2 activity.58 The experimen-
tal ﬁ  nding is in keeping with a previous report showing no 
increases in plasma Ang II levels in patients treated with 
olmesartan for 2 years.94 This novel ﬁ  nding contrasts with 
the known effects of ARBs in increasing plasma levels of 
Ang II.95 Altogether, the data suggest that the molecular 
characteristics of olmesartan medoxomil confer this drug 
with unique properties that translate into a greater speciﬁ  c-
ity and actions.
Studies in a wide range of animal models have 
demonstrated that treatment with olmesartan signiﬁ  cantly 
reduces inﬂ  ammation, prevents formation of new lesions, 
and promotes regression of pre-existing atherosclerotic 
lesions. Improvements have been demonstrated in animal 
models of atherosclerosis, hypertension, diabetes mellitus, 
nephropathy, and retinopathy. Studies in animals have also 
shown that the combination of olmesartan and pravastatin 
has complementary pleiotropic effects on the progression 
of atherosclerosis. Olmesartan reduces inﬂ  ammation, while 
pravastatin inhibits progression of pre-existing lesions.
Olmesartan medoxomil produces long-lasting and 
clinically significant reductions in BP in patients with 
hypertension. It is now clear that broad-based improvements 
in endothelial dysfunction are also obtained in patients with 
hypertension that are independent of the BP-lowering effects 
of the drug. In the randomized, placebo-controlled EUTOPIA 
trial, olmesartan medoxomil signiﬁ  cantly reduced vascular 
inﬂ  ammation in patients with hypertension. The drug did 
not signiﬁ  cantly reduce the CC-IMT compared with atenolol 
after 2 years of continuous treatment in the large randomized 
MORE study. However, olmesartan medoxomil did produce 
signiﬁ  cant reductions in the volume of large atherosclerotic 
plaques compared with atenolol in patients enrolled in this 
trial. In the VIOS study, 1 year of treatment with olmesartan 
medoxomil restored the normal morphology of resistance 
vessels in patients with hypertension. WW, MCSA, and the 
W/L ratio of arteries decreased signiﬁ  cantly in recipients of 
olmesartan medoxomil, but not atenolol. Moreover, the W/L 
ratio in olmesartan medoxomil-treated patients was restored 
to the same dimensions as that in normotensive controls at 
the end of the study. Clinical studies in patients have also 
shown that olmesartan medoxomil signiﬁ  cantly increased the 
number of regenerative EPCs in the peripheral circulation and 
improves endothelium-dependent relaxation. Importantly, 
the positive beneﬁ  ts of olmesartan medoxomil on improving 
endothelial dysfunction appear to be independent of BP 
lowering.
Acknowledgments
The preparation of this article was supported by Daiichi 
Sankyo, Inc. I thank Blair Jarvis, MSc, and Alan J Klopp, 
PhD, for providing editorial assistance in the preparation of 
this review.
Disclosures
The author declares no conﬂ  icts of interest.
References
  1.  Hardoon SL, Whincup PH, Lennon LT, Wannamethee SG, Capewell S, 
Morris RW. How much of the recent decline in the incidence of myocardial 
infarction in British men can be explained by changes in cardiovascular 
risk factors? Evidence from a prospective population-based study. 
Circulation. 2008;117(5):598–604.
  2.  Kahn R, Robertson RM, Smith R, Eddy D. The impact of prevention 
on reducing the burden of cardiovascular disease. Circulation. 
2008;118(5):576–585.
 3.  Perkovic V, Huxley R, Wu Y, Prabhakaran D, MacMahon S. The 
burden of blood pressure-related disease: a neglected priority for 
global health. Hypertension. 2007;50(6):991–997.
 4.  Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney 
disease in the United States. JAMA. 2007;298(17):2038–2047.
  5.  Fox CS, Coady S, Sorlie PD, et al. Increasing cardiovascular disease 
burden due to diabetes mellitus: the Framingham Heart Study. 
Circulation. 2007;115(12):1544–1550.
  6.  Kestenbaum B, Rudser KD, de Boer IH, et al. Differences in kidney 
function and incident hypertension: The Multi-Ethnic Study of 
Atherosclerosis. Ann Intern Med. 2008;148(7):501–508.
  7.  Munzel T, Sinning C, Post F, Warnholtz A, Schulz E. Pathophysiology, 
diagnosis and prognostic implications of endothelial dysfunction. Ann 
Med. 2008;40(3):180–196.
 8.  Pahkala K, Heinonen OJ, Lagstrom H, et al. Vascular endothelial 
function and leisure-time physical activity in adolescents. Circulation. 
2008;118(23):2353–2359.
 9.  Halcox JP, Schenke WH, Zalos G, et al. Prognostic value of 
coronary vascular endothelial dysfunction. Circulation. 2002;106(6):
653–658.Vascular Health and Risk Management 2009:5 312
Ferrario
10.  Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction 
of clinical cardiovascular events with carotid intima-media thickness: 
a systematic review and meta-analysis. Circulation. 2007;115(4):459–467.
11.  McAllister AS, Atkinson AB, Johnston GD, Hadden DR, Bell PM, 
McCance DR. Basal nitric oxide production is impaired in offspring 
of patients with essential hypertension. Clin Sci (Lond). 1999;97(2):
141–147.
12.  Schlaich MP, Parnell MM, Ahlers BA, et al. Impaired L-arginine 
transport and endothelial function in hypertensive and genetically 
predisposed normotensive subjects. Circulation. 2004;110(24):
3680–3686.
13.  Yang Z, Venardos K, Jones E, Morris BJ, Chin-Dusting J, Kaye DM. 
Identiﬁ  cation of a novel polymorphism in the 3’UTR of the L-arginine 
transporter gene SLC7A1: contribution to hypertension and endothelial 
dysfunction. Circulation. 2007;115(10):1269–1274.
14.  Zhang C. The role of inﬂ  ammatory cytokines in endothelial dysfunc-
tion. Basic Res Cardiol. 2008;103(5):398–406.
15.  Ferrario CM, Richmond RS, Smith R, Levy P, Strawn WB, 
Kivlighn S. Renin-angiotensin system as a therapeutic target in manag-
ing atherosclerosis. Am J Ther. 2004;11(1):44–53.
16.  Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone 
system and proinﬂ  ammatory mediators in cardiovascular disease. 
Am J Cardiol. 2006;98(1):121–128.
17.  Strawn WB, Dean RH, Ferrario CM. Novel mechanisms linking 
angiotensin II and early atherogenesis. J Renin Angiotensin Aldosterone 
Syst. 2000;1(1):11–17.
18.  Strawn WB, Ferrario CM. Mechanisms linking angiotensin II and 
atherogenesis. Curr Opin Lipidol. 2002;13(5):505–512.
19.  Humphrey JD. Mechanisms of arterial remodeling in hypertension: 
coupled roles of wall shear and intramural stress. Hypertension. 
2008;52(2):195–200.
20.  Abuissa H, Jones PG, Marso SP, O’Keefe JH, Jr. Angiotensin-
converting enzyme inhibitors or angiotensin receptor blockers for 
prevention of type 2 diabetes: a meta-analysis of randomized clinical 
trials. J Am Coll Cardiol. 2005;46(5):821–826.
21.  Schupp M, Clemenz M, Gineste R, et al. Molecular characterization 
of new selective peroxisome proliferator-activated receptor gamma 
modulators with angiotensin receptor blocking activity. Diabetes. 
2005;54(12):3442–3452.
22.  Schupp M, Lee LD, Frost N, et al. Regulation of peroxisome 
proliferator-activated receptor gamma activity by losartan metabolites. 
Hypertension. 2006;47(3):586–589.
23.  Engeli S, Bohnke J, Gorzelniak K, et al. Weight loss and the renin-
angiotensin-aldosterone system. Hypertension. 2005;45(3):356–362.
24.  Engeli S, Schling P, Gorzelniak K, et al. The adipose-tissue 
renin-angiotensin-aldosterone system: role in the metabolic syndrome? 
Int J Biochem Cell Biol. 2003;35(6):807–825.
25.  Sharma AM. Is there a rationale for angiotensin blockade in the 
management of obesity hypertension? Hypertension. 2004;44(1):12–19.
26.  Sharma AM, Engeli S. The role of renin-angiotensin system blockade 
in the management of hypertension associated with the cardiometa-
bolic syndrome. J Cardiometab Syndr. 2006;1(1):29–35.
27.  Varagic J, Trask AJ, Jessup JA, Chappell MC, Ferrario CM. New 
angiotensins. J Mol Med. 2008;86(6):663–671.
28.  Imanishi T, Hano T, Nishio I. Angiotensin II accelerates endothelial 
progenitor cell senescence through induction of oxidative stress. 
J Hypertens. 2005;23(1):97–104.
29.  Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity 
of circulating endothelial progenitor cells inversely correlate with risk 
factors for coronary artery disease. Circ Res. 2001;89(1):E1–E7.
30. Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrario CM. Inhibition 
of early atherogenesis by losartan in monkeys with diet-induced 
hypercholesterolemia. Circulation. 2000;101(13): 1586–1593.
31.  Wassmann S, Czech T, van Eickels M, Fleming I, Bohm M, Nickenig G. 
Inhibition of diet-induced atherosclerosis and endothelial dysfunction 
in apolipoprotein E/angiotensin II type 1A receptor double-knockout 
mice. Circulation. 2004;110(19):3062–3067.
32. Richmond  RS, Tallant EA, Gallagher PE, Ferrario CM, Strawn WB. 
Angiotensin II stimulates arachidonic acid release from bone marrow 
stromal cells. J Renin Angiotensin Aldosterone Syst. 2004;5(4):176–182.
33. Strawn  WB, Richmond RS, Ann Tallant E, Gallagher PE, Ferrario CM. 
Renin-angiotensin system expression in rat bone marrow haematopoi-
etic and stromal cells. Br J Haematol. 2004;126(1):120–126.
34.  Strawn WB, Ferrario CM. Angiotensin II AT1 receptor blockade 
normalizes CD11b+ monocyte production in bone marrow of hyper-
cholesterolemic monkeys. Atherosclerosis. 2008;196(2):624–632.
35.  Santos RA, Simoes e Silva AC, Maric C, et al. Angiotensin-(1–7) is 
an endogenous ligand for the G protein-coupled receptor Mas. Proc 
Natl Acad Sci U S A. 2003;100(14):8258–8263.
36.  Santos RA, Castro CH, Gava E, et al. Impairment of in vitro and in 
vivo heart function in angiotensin-(1–7) receptor MAS knockout mice. 
Hypertension. 2006;47(5):996–1002.
37.  Castro CH, Santos RA, Ferreira AJ, Bader M, Alenina N, Almeida AP. 
Evidence for a functional interaction of the angiotensin-(1–7) receptor 
Mas with AT1 and AT2 receptors in the mouse heart. Hypertension. 
2005;46(4):937–942.
38.  Dias-Peixoto MF, Santos RA, Gomes ER, et al. Molecular mechanisms 
involved in the angiotensin-(1–7)/Mas signaling pathway in 
cardiomyocytes. Hypertension. 2008;52(3):542–548.
39.  Gallagher PE, Ferrario CM, Tallant EA. MAP Kinase/phosphatase 
pathway mediates the regulation of ACE2 by angiotensin peptides. 
Am J Physiol Cell Physiol. 2008;295(5):C1169–C1174.
40.  Sampaio WO, Henrique de Castro C, Santos RA, Schiffrin EL, 
Touyz RM. Angiotensin-(1–7) counterregulates angiotensin II signal-
ing in human endothelial cells. Hypertension. 2007;50(6):1093–1098.
41.  Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting 
enzyme 2 is an essential regulator of heart function. Nature. 
2002;417(6891):822–828.
42.  Ferrario CM. Angiotensin-converting enzyme 2 and angiotensin-
(1–7): an evolving story in cardiovascular regulation. Hypertension. 
2006;47(3):515–521.
43. Lu  H,  Rateri DL, Feldman DL, et al. Renin inhibition reduces 
hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest. 
2008;118(3):984–993.
44.  Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on 
renal and cardiovascular outcomes in patients with type 2 diabetes and 
nephropathy. N Engl J Med. 2001;345(12):861–869.
45.  Cohn JN, Tognoni G. A randomized trial of the angiotensin-
receptor blocker valsartan in chronic heart failure. N Engl J Med. 
2001;345(23):1667–1675.
46.  Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality 
and morbidity in high-risk patients after acute myocardial infarction: the 
OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction 
with Angiotensin II Antagonist Losartan. Lancet. 2002;360(9335): 
752–760.
47.  Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of 
the angiotensin-receptor antagonist irbesartan in patients with nephrop-
athy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–860.
48.  Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, 
Arner P. The effect of irbesartan on the development of diabetic 
nephropathy in patients with type 2 diabetes. N Engl J Med. 
2001;345(12):870–878.
49. Pfeffer  MA,  McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or 
both in myocardial infarction complicated by heart failure, left ventric-
ular dysfunction, or both. N Engl J Med. 2003;349(20):1893–1906.
50.  Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan 
on mortality and morbidity in patients with chronic heart failure: the 
CHARM-Overall programme. Lancet. 2003;362(9386):759–766.
51. The_ONTARGET_Investigators. Telmisartan, ramipril, or both in 
patients at high risk for vascular events. N Engl J Med. 2008;358:
1547–1559.
52.  Strawn WB, Ferrario CM, Tallant EA. Angiotensin-(1–7) reduces 
smooth muscle growth after vascular injury. Hypertension. 1999; 
33(1 Pt 2):207–211.Vascular Health and Risk Management 2009:5 313
Olmesartan medoxomil improves endothelial dysfunction
53.  Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, 
Ferrario CM. Upregulation of angiotensin-converting enzyme 2 
after myocardial infarction by blockade of angiotensin II receptors. 
Hypertension. 2004;43(5):970–976.
54.  Ferrario CM, Trask AJ, Jessup JA. Advances in biochemical and func-
tional roles of angiotensin-converting enzyme 2 and angiotensin-(1–7) 
in regulation of cardiovascular function. Am J Physiol Heart Circ 
Physiol. 2005;289(6):H2281–H2290.
55.  Igase M, Strawn WB, Gallagher PE, Geary RL, Ferrario CM. 
Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1–7) 
expression in the aorta of spontaneously hypertensive rats. Am J 
Physiol Heart Circ Physiol. 2005;289(3):H1013–H1019.
56.  Tallant EA, Ferrario CM, Gallagher PE. Angiotensin-(1–7) inhibits 
growth of cardiac myocytes through activation of the mas receptor. 
Am J Physiol Heart Circ Physiol. 2005;289(4):H1560–H1566.
57.  Yokoyama H, Averill DB, Brosnihan KB, Smith RD, Schiffrin EL, 
Ferrario CM. Role of blood pressure reduction in prevention of cardiac 
and vascular hypertrophy. Am J Hypertens. 2005;18(7):922–929.
58.  Agata J, Ura N, Yoshida H, et al. Olmesartan is an angiotensin II 
receptor blocker with an inhibitory effect on angiotensin-converting 
enzyme. Hypertens Res. 2006;29(11):865–874.
59.  Trask AJ, Averill DB, Ganten D, Chappell MC, Ferrario CM. Primary 
role of angiotensin-converting enzyme-2 in cardiac production of 
angiotensin-(1–7) in transgenic Ren-2 hypertensive rats. Am J Physiol 
Heart Circ Physiol. 2007;292(6):H3019–H3024.
60.  Trask AJ, Ferrario CM. Angiotensin-(1–7): pharmacology and new 
perspectives in cardiovascular treatments. Cardiovasc Drug Rev. 
2007;25(2):162–174.
61.  Gallagher PE, Ferrario CM, Tallant EA. Regulation of ACE2 in 
cardiac myocytes and ﬁ  broblasts. Am J Physiol Heart Circ Physiol. 
2008;295(6):H2373–H2379.
62.  Igase M, Kohara K, Nagai T, Miki T, Ferrario CM. Increased expression 
of angiotensin converting enzyme 2 in conjunction with reduction of 
neointima by angiotensin II type 1 receptor blockade. Hypertens Res. 
2008;31(3):553–559.
63.  Fliser D, Buchholz K, Haller H. Antiinflammatory effects of 
angiotensin II subtype 1 receptor blockade in hypertensive patients 
with microinﬂ  ammation. Circulation. 2004;110(9):1103–1107.
64.  Bahlmann FH, de Groot K, Mueller O, Hertel B, Haller H, Fliser D. 
Stimulation of endothelial progenitor cells: a new putative thera-
peutic effect of angiotensin II receptor antagonists. Hypertension. 
2005;45(4):526–529.
65.  Stumpe K, Agabiti-Rosei E, Zielinski T, et al. Carotid intima-media 
thickness and plaque volume changes following 2-year angiotensin II-
receptor blockade. The multicentre olmesartan atherosclerosis regress-
sion evaluation (MORE) study. Ther Adv Cardiovasc Dis. 2007;
1(2):97–106.
66.  Naya M, Tsukamoto T, Morita K, et al. Olmesartan, but not amlodip-
ine, improves endothelium-dependent coronary dilation in hyperten-
sive patients. J Am Coll Cardiol. 2007;50(12):1144–1149.
67.  Smith R, Yokoyama H, Averill DB, Schiffrin EL, Ferrario CM. Reversal 
of vascular hypertrophy in hypertensive patients through blockade of 
angiotensin II receptors. JASH. 2008;2(3):165–172.
68.  Smith RD, Yokoyama H, Averill DB, et al. The protective effects of 
angiotensin II blockade with olmesartan medoxomil on resistance vessel 
remodeling (The VIOS study): rationale and baseline characteristics. 
Am J Cardiovasc Drugs. 2006;6(5):335–342.
69. Yamamoto E, Dong YF, Kataoka K, et al. Olmesartan prevents 
cardiovascular injury and hepatic steatosis in obesity and diabetes, 
accompanied by apoptosis signal regulating kinase-1 inhibition. 
Hypertension. 2008;52(3):573–580.
70.  Izumiya Y, Kim S, Izumi Y, et al. Apoptosis signal-regulating kinase 1 
plays a pivotal role in angiotensin II-induced cardiac hypertrophy and 
remodeling. Circ Res. 2003;93(9):874–883.
71.  Porteri E, Rodella L, Rizzoni D, et al. Effects of olmesartan and enalapril 
at low or high doses on cardiac, renal and vascular interstitial matrix in 
spontaneously hypertensive rats. Blood Press. 2005;14(3):184–192.
72.  Yoshida J, Yamamoto K, Mano T, et al. AT1 receptor blocker added 
to ACE inhibitor provides beneﬁ  ts at advanced stage of hypertensive 
diastolic heart failure. Hypertension. 2004;43(3):686–691.
73.  Miyazaki M, Takai S. Anti-atherosclerotic efﬁ  cacy of olmesartan. 
J Hum Hypertens. 2002;16 Suppl 2:S7–S12.
74.  Takai S, Jin D, Sakaguchi M, Muramatsu M, Miyazaki M. The 
regressive effect of an angiotensin II receptor blocker on formed 
fatty streaks in monkeys fed a high-cholesterol diet. J Hypertens. 
2005;23(10):1879–1886.
75.  Kato M, Sada T, Mizuno M, Kitayama K, Inaba T, Koike H. Effect of 
combined treatment with an angiotensin II receptor antagonist and an 
HMG-CoA reductase inhibitor on atherosclerosis in genetically hyper-
lipidemic rabbits. J Cardiovasc Pharmacol. 2005;46(4):556–562.
76.  van der Hoorn JW, Kleemann R, Havekes LM, Kooistra T, Princen HM, 
Jukema JW. Olmesartan and pravastatin additively reduce development 
of atherosclerosis in APOE*3Leiden transgenic mice. J Hypertens. 
2007;25(12):2454–2462.
77. Yamamoto E, Yamashita T, Tanaka T, et al. Pravastatin enhances 
beneﬁ  cial effects of olmesartan on vascular injury of salt-sensitive 
hypertensive rats, via pleiotropic effects. Arterioscler Thromb Vasc 
Biol. 2007;27(3):556–563.
78.  Tsuda M, Iwai M, Li JM, et al. Inhibitory effects of AT1 receptor 
blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative 
stress. Hypertension. 2005;45(4):545–551.
79.  Kato M, Sada T, Chuma H, et al. Severity of hyperlipidemia does 
not affect antiatherosclerotic effect of an angiotensin II receptor 
antagonist in apolipoprotein E-deﬁ  cient mice. J Cardiovasc Pharmacol. 
2006;47(6):764–769.
80.  Koga K, Yamagishi S, Takeuchi M, et al. CS-886, a new angiotensin II 
type 1 receptor antagonist, ameliorates glomerular anionic site loss and 
prevents progression of diabetic nephropathy in Otsuka Long-Evans 
Tokushima fatty rats. Mol Med. 2002;8(10):591–599.
81.  Kobori H, Ozawa Y, Suzaki Y, Nishiyama A. Enhanced intrarenal 
angiotensinogen contributes to early renal injury in spontaneously 
hypertensive rats. J Am Soc Nephrol. 2005;16(7):2073–2080.
82.  Nangaku M, Miyata T, Sada T, et al. Anti-hypertensive agents inhibit 
in vivo the formation of advanced glycation end products and improve 
renal damage in a type 2 diabetic nephropathy rat model. J Am Soc 
Nephrol. 2003;14(5):1212–1222.
83.  Izuhara Y, Nangaku M, Inagi R, et al. Renoprotective properties of 
angiotensin receptor blockers beyond blood pressure lowering. J Am 
Soc Nephrol. 2005;16(12):3631–3641.
84. Nakamura H, Inoue T, Arakawa N, et al. Pharmacological and 
pharmacokinetic study of olmesartan medoxomil in animal diabetic 
retinopathy models. Eur J Pharmacol. 2005;512(2–3):239–246.
85.  Jinno T, Iwai M, Li Z, et al. Calcium channel blocker azelnidipine 
enhances vascular protective effects of AT1 receptor blocker olmes-
artan. Hypertension. 2004;43(2):263–269.
86. Liu  HW,  Iwai M, Takeda-Matsubara Y, et al. Effect of estrogen 
and AT1 receptor blocker on neointima formation. Hypertension. 
2002;40(4):451–457.
87.  Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, Horiuchi M. Aldosterone 
and angiotensin II synergistically induce mitogenic response in vascular 
smooth muscle cells. Circ Res. 2005;97(5):434–442.
88. Mukai Y, Shimokawa H, Higashi M, et al. Inhibition of renin-
angiotensin system ameliorates endothelial dysfunction associated with 
aging in rats. Arterioscler Thromb Vasc Biol. 2002;22(9):1445–1450.
89.  Ferrario CM. The role of angiotensin antagonism in stroke prevention 
in patients with hypertension: focus on losartan. Curr Med Res Opin. 
2004;20(11):1797–1804.
90.  Fabia MJ, Abdilla N, Oltra R, Fernandez C, Redon J. Antihypertensive 
activity of angiotensin II AT1 receptor antagonists: a systematic review 
of studies with 24 h ambulatory blood pressure monitoring. J Hypertens. 
2007;25(7):1327–1336.
91.  Koike H, Sada T, Mizuno M. In vitro and in vivo pharmacology of 
olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist. 
J Hypertens Suppl. 2001;19(1):S3–S14.Vascular Health and Risk Management 2009:5 314
Ferrario
92. Yanagisawa H, Amemiya Y, Kanazaki T, et al. Nonpeptide 
angiotensin II receptor antagonists: synthesis, biological activities, 
and structure-activity relationships of imidazole-5-carboxylic acids 
bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position 
and their related compounds. J Med Chem. 1996;39(1):323–338.
93. Le  MT, Pugsley MK, Vauquelin G, Van Liefde I. Molecular 
characterisation of the interactions between olmesartan and telmisartan 
and the human angiotensin II AT1 receptor. Br J Pharmacol. 
2007;151(7):952–962.
94.  Ichikawa S, Takayama Y. Long-term effects of olmesartan, an Ang II 
receptor antagonist, on blood pressure and the renin-angiotensin-
aldosterone system in hypertensive patients. Hypertens Res. 2001;
24(6):641–646.
95.  Schindler C, Brosnihan KB, Ferrario CM, et al. Comparison of inhibitory 
effects of irbesartan and atorvastatin treatment on the renin angiotensin 
system (RAS) in veins: a randomized double-blind crossover trial in 
healthy subjects. J Clin Pharmacol. 2007;47(1):112–120.
96.  Iyer SN, Averill DB, Chappell MC, Yamada K, Allred AJ, Ferrario CM. 
Contribution of angiotensin-(1–7) to blood pressure regulation in salt-
depleted hypertensive rats. Hypertension. 2000;36(3):417–422.
97.  Moriguchi A, Tallant EA, Matsumura K, et al. Opposing actions 
of angiotensin-(1–7) and angiotensin II in the brain of transgenic 
hypertensive rats. Hypertension. 1995;25(6):1260–1265.
98.  Campagnole-Santos MJ, Heringer SB, Batista EN, Khosla MC, 
Santos RA. Differential baroreceptor reﬂ  ex modulation by centrally 
infused angiotensin peptides. Am J Physiol. 1992;263(1 Pt 2):R89–R94.
99.  Grobe JL, Mecca AP, Lingis M, et al. Prevention of angiotensin 
II-induced cardiac remodeling by angiotensin-(1–7). Am J Physiol 
Heart Circ Physiol. 2007;292(2):H736–H742.
100.  Ferreira AJ, Santos RA, Almeida AP. Angiotensin-(1–7): cardioprotective 
effect in myocardial ischemia/reperfusion. Hypertension. 2001;38(3 Pt 2):
665–668.
101. Ferreira AJ, Santos RA, Almeida AP. Angiotensin-(1–7) improves 
the post-ischemic function in isolated perfused rat hearts. Braz J Med 
Biol Res. 2002;35(9):1083–1090.
102. DelliPizzi AM, Hilchey SD, Bell-Quilley CP. Natriuretic action of 
angiotensin(1–7). Br J Pharmacol. 1994;111(1):1–3.
103.  Heller J, Kramer HJ, Maly J, Cervenka L, Horacek V. Effect of 
intrarenal infusion of angiotensin-(1–7) in the dog. Kidney Blood 
Press Res. 2000;23(2):89–94.
104.  Vallon V, Heyne N, Richter K, Khosla MC, Fechter K. [7-D-ALA]-
angiotensin 1–7 blocks renal actions of angiotensin 1–7 in the 
anesthetized rat. J Cardiovasc Pharmacol. 1998;32(1):164–167.
105.  Loot AE, Roks AJ, Henning RH, et al. Angiotensin-(1–7) attenuates 
the development of heart failure after myocardial infarction in rats. 
Circulation. 2002;105(13):1548–1550.
106. Ferrario CM, Martell N, Yunis C, et al. Characterization of angiotensin-
(1–7) in the urine of normal and essential hypertensive subjects. Am 
J Hypertens. 1998;11(2):137–146.
107.  Luque M, Martin P, Martell N, Fernandez C, Brosnihan KB, Ferrario 
CM. Effects of captopril related to increased levels of prostacyclin 
and angiotensin-(1–7) in essential hypertension. J Hypertens. 
1996;14(6):799–805.
108. Ferrario CM, Smith RD, Brosnihan B, et al. Effects of omapatrilat 
on the renin-angiotensin system in salt-sensitive hypertension. Am J 
Hypertens. 2002;15(6):557–564.
109.  Schmeider RE, Hilgers KF, Schlaich MP. Renin-angiotensin system 
and cardiovascular risk. Lancet. 2007;369:1208–1219.